AbbVie and Gubra A/S sign agreement to develop potential obesity treatment, GUB014295

From Nasdaq: 2025-03-03 01:26:52

AbbVie and Gubra A/S have entered a license agreement to develop GUB014295, a potential long-acting amylin analog for treating obesity. AbbVie will lead global development and commercialization, with Gubra receiving $350 million upfront and up to $1.875 billion in milestone payments, plus royalties. GUB014295 is currently in Phase 1 trials. Gubra, listed on Nasdaq Copenhagen, specializes in pre-clinical research and peptide-based drug discovery for metabolic and fibrotic diseases. Stay updated on health news at rttnews.com. Please note that the views expressed here are those of the author and not necessarily Nasdaq, Inc.



Read more at Nasdaq: AbbVie, Gubra Enter License Agreement To Develop GUB014295 – Quick Facts